F. Hsu

发表

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

R. Houot, J. Briones, C. Flowers, 2021, Leukemia & lymphoma.

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.

R. Levy, D. Czerwinski, J. Timmerman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rationale for Anti-TGF-β Antibody Therapy in Oncology

B. Teicher, J. McPherson, F. Hsu, 2008 .

Clonal VDJ recombination of the immunoglobulin heavy chain gene by PCR in classical Hodgkin's disease.

R. Warnke, M. van de Rijn, F. Hsu, 1995, American journal of clinical pathology.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

A. Nademanee, J. Dipersio, G. Bridger, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

B. Wood, D. Dale, A. Bolyard, 2011, Blood.

Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.

Robin L. Jones, G. Shapiro, P. Hwu, 2015 .

Rapid cytotoxicity of human B lymphocytes induced by VH4‐34 (VH4.21) gene‐encoded monoclonal antibodies, II

C. Chapman, N. Teng, F. Stevenson, 1997, Clinical and experimental immunology.

Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.

E. Engleman, T. Davis, C. Benike, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CTLA4 Blockade Maximizes Antitumor T-Cell Activation by Dendritic Cells Presenting Idiotype Protein or Opsonized Anti-CD20 Antibody-Coated Lymphoma Cells

F. Hsu, M. Komarovskaya, 2002, Journal of immunotherapy.

Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.

A. Nademanee, J. Dipersio, G. Bridger, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.

D. Czerwinski, E. Engleman, T. Davis, 2002, Blood.

Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma.

F. Hsu, R. Levy, Ronald Levy, 1995, Blood.

Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma

D. Byrd, P. Nghiem, Hailing Lu, 2018, Clinical Cancer Research.

Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses

Hailing Lu, J. Meulen, Idit Sagiv-Barfi, 2015 .

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

J. Berzofsky, T. Olencki, G. Shapiro, 2015, Cancer Immunology, Immunotherapy.

Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma.

A. Krensky, L. Kwak, C. Clayberger, 1996, Blood.

Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

Edgar G. Engleman, Ronald Levy, Francesco Fagnoni, 1996, Nature Medicine.

Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.

D. Czerwinski, L. Kwak, T. Liles, 1997, Blood.

Relevance and Clinical Implications of Tumor Cell Mobilization in Autologous Transplantation of Multiple Myeloma and Non-Hodgkin’s Lymphoma

J. Dipersio, A. Ho, S. Fruehauf, 2012 .

Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting.

J. Dipersio, A. Ho, S. Fruehauf, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment

M. Konopleva, M. Andreeff, M. Shikami, 2013, PloS one.

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1

Robin L. Jones, G. Shapiro, P. Hwu, 2019, Clinical Cancer Research.

Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGF{beta}) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC)

J. Berzofsky, T. Olencki, M. Reiss, 2008 .

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

J. Berzofsky, T. Olencki, M. Reiss, 2014, PloS one.

Pilot trial of intratumoral (IT) G100, a toll-like receptor-4 (TLR4) agonist, in patients (pts) with Merkel cell carcinoma (MCC): Final clinical results and immunologic effects on the tumor microenvironment (TME).

D. Byrd, Hailing Lu, U. Parvathaneni, 2016 .

Clinical Trials of Idiotype‐Specific Vaccine in B‐Cell Lymphomas

L. Kwak, M. Campbell, T. Liles, 1993, Annals of the New York Academy of Sciences.